A 14-year-old girl with metastatic renal cell carcinoma was treated with nephrectomy, interferon, and several lines of the targeted agents sorafenib, bevacizumab, sunitinib, and everolimus, either alone or in combination. Treatment was well tolerated, but the patient developed hypothyroidism and significant hypertension with bevacizumab and sunitinib. She responded to all agents and was given radiation treatment twice at the time of symptomatic disease progression; she died 33 months from diagnosis.
Continuing Response to Subsequent Treatment Lines With Tyrosine Kinase Inhibitors in an Adolescent With Metastatic Renal Cell Carcinoma / Maria Debora De, Pasquale; Rosanna, Pessolano; Renata, Boldrini; Ilaria, Ilari; Alberto, Donfrancesco; Cortesi, Enrico; Alessandro, Jenkner. - In: JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY. - ISSN 1077-4114. - STAMPA. - 33:5(2011), pp. e176-e179. [10.1097/mph.0b013e3182028fd9]
Continuing Response to Subsequent Treatment Lines With Tyrosine Kinase Inhibitors in an Adolescent With Metastatic Renal Cell Carcinoma
CORTESI, Enrico;
2011
Abstract
A 14-year-old girl with metastatic renal cell carcinoma was treated with nephrectomy, interferon, and several lines of the targeted agents sorafenib, bevacizumab, sunitinib, and everolimus, either alone or in combination. Treatment was well tolerated, but the patient developed hypothyroidism and significant hypertension with bevacizumab and sunitinib. She responded to all agents and was given radiation treatment twice at the time of symptomatic disease progression; she died 33 months from diagnosis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
